XSpray Pharma AB (XSPRAY) — Cash Flow-to-Debt Ratio
XSpray Pharma AB (XSPRAY) has a Cash Flow-to-Debt Ratio of -0.18x as of March 2026, meaning its operating cash flow of Skr-30.68 Million could theoretically repay 0% of its total liabilities (Skr167.03 Million) in one year. Check XSpray Pharma AB (XSPRAY) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
XSpray Pharma AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for XSpray Pharma AB across 11 annual periods. Also explore XSpray Pharma AB assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for XSpray Pharma AB (2015–2025)
Year-by-year debt coverage analysis for XSpray Pharma AB. For market capitalisation and broader financial context, see how much is XSpray Pharma AB worth.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.17x | Skr-193.16 Million | Skr164.70 Million | ▲ +8.6% |
| 2024 | -1.28x | Skr-222.37 Million | Skr173.25 Million | ▲ +54.6% |
| 2023 | -2.83x | Skr-203.28 Million | Skr71.85 Million | ▲ +24.5% |
| 2022 | -3.75x | Skr-110.18 Million | Skr29.41 Million | ▼ -126.1% |
| 2021 | -1.66x | Skr-51.61 Million | Skr31.15 Million | ▲ +21.3% |
| 2020 | -2.10x | Skr-47.79 Million | Skr22.72 Million | ▼ -65.7% |
| 2019 | -1.27x | Skr-34.24 Million | Skr26.96 Million | ▲ +22.9% |
| 2018 | -1.65x | Skr-17.75 Million | Skr10.77 Million | ▲ +14.1% |
| 2017 | -1.92x | Skr-11.04 Million | Skr5.75 Million | ▼ -492.8% |
| 2016 | -0.32x | Skr-1.74 Million | Skr5.39 Million | ▲ +93.3% |
| 2015 | -4.82x | Skr-12.96 Million | Skr2.69 Million | — |